Korean J healthc assoc Infect Control Prev.  2023 Dec;28(2):226-232. 10.14192/kjicp.2023.28.2.226.

A Study on the Status and Genetic Characteristics of Carbapenem Resistance of Clinical-derived Bacteria in Northern Gyeonggi Province

• Lee Cm
• Kim KA
• Oh SH
• Jang MJ
• You SH
• Park HB
• Ko DJ

• KMID: 2549950
• DOI: http://doi.org/10.14192/kjicp.2023.28.2.226

Abstract

Background
Carbapenem-resistant Enterobacterales (CRE) is an infectious disease caused by an Enterobacteriaceae species resistant to one or more of the carbapenem antibiotics.
Methods
Strains collected in clinical trials from 2018 to 2022 in the northern Gyeonggi region were tested. CRE strain identification was performed using 16s rRNA sequencing or VITEK2 (BioMerieux, France). The antibiotic minimum inhibitory concentrations were confirmed using the broth microdilution method, and polymerase chain reaction was performed to detect carbapenemase (CPE) genes.
Results
Throughout the five-year period, CRE infections continued to spread in northern Gyeonggi Province, and the proportion of strains containing CPE genes also increased. The dominant strain causing communicable infection were K. pneumoniae, E. coli, and E. cloacae complex, and the CPE genes influencing infection were KPC, NDM, and OXA. The genotype distribution of CRE-positive species indicated that K. pneumoniae-KPC-2 was the most common. Carbapenem antibiotic resistance analysis revealed that the Ertapenem-ImipenemMeropenem-Doripenem type, which is resistant to all four antibiotics, is the most common at 52.3%.
Conclusion
This study confirmed that CRE infection has continued to spread in medical institutions in northern Gyeonggi Province over the past five years. CRE can cause clinical infections with a variety of serious complications. In addition, patients with CRE have difficulty in treatment due to the limited availability of antibiotics. Continuous monitoring of the epidemic and patient management are necessary to prevent antibiotic resistance.

Keyword

Carbapenem-resistant Enterobacterales (CRE); Carbapenemase-producing Enterobacterales (CPE)

Reference

1. Korea Disease Control. Carbapenem-resistant Enterobacteriaceae (CRE). https://npt.kdca.go.kr/npt/biz/npp/portal/nppSumryMain.do?icdCd=NB0020&icdgrpCd=02&icdSubgrpCd=. (Updated on 10 September 2020).

2. Park SY. 2019. Apr. 26-27. Infection and management of carbapenem-resistant intestinal bacteria. Paper presented at: Spring academic conference of the Korean association of internal medicine. Busan, Korea: 249–51.

3. Park JW, Lee EJ, Lee SJ, Lee HM. 2017; Status of carbapenemase-producing Enterobacteriaceae incidences in Korea, 2015-2016. Public Health Wkly Rep. 10:1243–7.

4. Korea Center for Disease Control & Prevention. 2012. Infection control guidelines for multidrug resistant microorganisms in healthcare facilities. Korea Center for Disease Control & Prevention;Cheongju: p. 17.

5. Korea Disease Control and Prevention Agency. 2022. Guidelines for management of infectious diseases 2022. Korea Disease Control and Prevention Agency;Cheongju: p. 56–7.

6. Lee HJ, Lee DG. 2018; Carbapenem-resistant Enterobacteriaceae: recent updates and treatment strategies. J Korean Med Assoc. 61:281–9. DOI: 10.5124/jkma.2018.61.4.281.

7. Park SJ. 2021. Genetic diversity of carbapenem-resistant Enterobactericeae isolated from a hospital in Busan. [master's thesis]. Dong-Eui University;Busan:

8. Lee AJ. 2019. Clinical characteristics and molecular epidemiology of carbapenemase-producing Enterobacteriaceae. [PhD dissertation]. Daegu Catholic University;Gyeongsan:

9. Go EB, Joo SJ, Hwang KJ, Park SD. 2020; Distributions of carbapenem-resistant Enterobacteriaceae (CRE) in Korea, 2019. Public Health Wkly Rep. 13:3348–55.

10. Woo KS. 2019; Carbapenem-resistant Enterobacteriaceae: rapid laboratory diagnosis and surveillance culture for infection control. Korean J Med. 94:170–2. DOI: 10.3904/kjm.2019.94.2.170.